Ordering Genetic Testing

This material is provided by UCSF Weill Institute for Neurosciences as an educational resource for health care providers.

UCSF Weill Institute for Neurosciences
Memory and Aging Center

Models for illustrative purposes only.
Ordering Genetic Testing

When is dementia genetic testing appropriate for my patient?

You might consider genetic testing for your patient if the following concerns arise:

- You are concerned your patient has a genetic form of dementia
- Your patient has a family member who was diagnosed with a genetic form of dementia

Genetic counseling is recommended before ordering any genetic test so that patients can understand the implications for all family members and can give proper informed consent. A genetic counselor or other genetics professional can provide genetic counseling. Either should have expertise in the genetics of dementia.

When is dementia genetic testing not appropriate for my patient?

Dementia with single gene etiology is rare. This makes genetic testing appropriate for a small proportion of individuals only. Genetic testing for pathogenic variants is warranted in certain situations. Genetic testing for risk variants is not recommended, even if a test is clinically available. Consider first whether or not your patient has symptoms.

1. Does your patient have symptoms?
   - Yes
   - No

2. Is your patient’s clinical syndrome and family history suggestive of dementia with a single gene cause [see Family Health History]?
   - No
   - Yes

3. Does your patient have an affected family member(s) in whom a single gene cause was previously identified by genetic testing?
   - Yes
   - No

Genetic testing is not appropriate.

- APOE gene testing is not recommended, though data from ongoing clinical trials support provision of testing, if accompanied by genetic counseling.
- Discuss availability of genetic research and/or DNA banking.

Recommended

Optional
Is APOE gene testing recommended?

The American College of Medical Genetics and Genomics (ACMG) and the National Society of Genetic Counselors (NSGC) recommend against APOE gene testing for your patients with no cognitive symptoms.

The APOE gene encodes a protein called apolipoprotein E (APOE), which is involved in lipid transport and serves as a scaffold for high-density lipoproteins (HDL). It is highly expressed in the liver and the CNS. APOE transports lipids in the body. It is also involved in the transport of amyloid beta, one of the pathological hallmarks of Alzheimer’s disease. The APOE gene has three common versions (alleles), called ε2, ε3, and ε4, which result in six possible genotypes. Frequencies of the three alleles vary, depending on ethnicity. Among Caucasians the most common APOE allele is ε3, followed by ε4 and then ε2. The ε4 allele is a risk factor for Alzheimer’s disease, with one or two copies conferring increased lifetime risk to develop the disease. The ε2 and ε3 variants do not increase risk for Alzheimer’s disease. Depending on ethnicity, about 15–20% of individuals in the general population carry one ε4 allele. This frequency increases to about 50% among individuals with Alzheimer’s disease.

Without reference to APOE, the lifetime risk among Caucasians to develop Alzheimer’s disease is 10–11% for men and 14–17% for women who live to age 85 years. Having one ε4 allele increases risk by 2-fold, approaching 23% for men and 35% for women who live to age 85 years. Having two ε4 alleles increases risk by 4- to 5-fold, approaching 52% for men and 68% for women who live to age 85 years. These risk estimates do not hold true for all populations, as allele frequencies and magnitude of risk conferred by the ε4 allele differ among ethnic groups. The ε4 allele decreases the age of onset of first symptoms. However, the ε4 allele does not cause Alzheimer’s disease directly. Overall risk of Alzheimer’s disease for your patient depends instead on a multitude of genetic, epigenetic, and environmental factors.

Among your patients with mild cognitive impairment, APOE ε4 carrier status by itself does not predict cognitive decline or conversion to Alzheimer’s disease. While APOE ε4 carrier status is considered by some clinicians a supportive adjunct to the clinical diagnosis of Alzheimer’s disease, current data to support such use are lacking.

APOE gene testing of your patients without cognitive symptoms is not recommended because of (1) poor predictive value of the test and (2) its limited clinical utility. Poor predictive value means ε4 carrier status does not forecast the development of Alzheimer’s disease. Limited clinical utility reflects the lack of definitive treatment or risk-reducing options for individuals with one or two APOE ε4 alleles. Genotyping is also not advised because of concerns about emotional effects of risk disclosure. However, research interest in Alzheimer’s disease prevention is flourishing. The prospect of therapies with differential response based on APOE genotype may bring changing attitudes about APOE testing.

Research suggests that the recommendation against APOE genotyping appears to contrast with lay attitudes, which reveal broad support of learning genetic susceptibility for Alzheimer’s disease. This is reflected by the large number of customers of direct-to-consumer (DTC) genetic testing companies offering APOE genotyping. Many consumers of DTC APOE testing are not dissuaded by its poor clinical utility. Many people pursue testing citing a desire to have information for future care and/or financial planning. Many cite a desire to provide information to family members. People may be more likely to obtain APOE genotyping if they can afford to pay for the test.

Researchers have begun to examine the effects of disclosing APOE genotype to individuals with no cognitive symptoms in a controlled setting. The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study, a series of multi-center randomized clinical trials collectively including over 1,100 individuals, demonstrated in a subset of people that APOE genotype and Alzheimer’s risk information can be provided after counseling and education without undue stress and misunderstandings. However, these study groups were small and selective. They excluded people with severe mood disorders and people with mild cognitive impairment. The study’s findings may not apply to the general population.

Take-home message

Many people worry about Alzheimer’s disease. As a concerned physician, you, together with your patient, will face questions about the patient’s risk to develop Alzheimer’s disease. Although APOE testing is clinically available, it is not advised. Direct-to-consumer APOE genotyping is also not advised [Goldman 2011]. APOE is a susceptibility gene, not a deterministic one. If your patient wishes to pursue APOE genotyping despite recommendations to the contrary, consider referring to a genetic counselor. Genetic counselors who are knowledgeable about dementia can provide counseling and education to your patients. The REVEAL trials suggested that genetic counselors are well suited to help your patients cope and adapt to the short-term emotional distress that may accompany genetic testing [Green 2014].

What research about the genetics of Alzheimer’s disease would be available to my patient?

The following resources provide information about Alzheimer’s disease research:

- The Alzheimer’s Association, alz.org
- Clinical Trials, clinicaltrials.gov

What is DNA banking?

DNA banking is the long-term storage of a person’s genetic material for possible future genetic testing. DNA is most frequently extracted from blood, but can also be obtained from cheek cells, saliva, or other tissues. Numerous commercial laboratories will store DNA for a fee during a pre-determined period of time. Once preserved, DNA can be sent for genetic testing at any time. There may be additional costs associated with transfer of DNA and subsequent genetic testing. DNA can be banked at any time during a person’s life, but may be urgent for the elderly and terminally ill. Once a person is buried or cremated, it may be difficult or impossible to obtain a DNA sample.

Reasons your patients and their families might consider DNA banking are as follows:
• Your patient or your patient’s relative has dementia, and death is imminent, leaving no time for standard genetic evaluation or testing, if appropriate.

• Your patient or your patient’s relative has dementia, and next-of-kin or legally authorized representative and other family members cannot agree on decisions about genetic testing, if appropriate.

• Limitations of current technology or disease knowledge have impeded the identification of a genetic cause of what appears to be an inherited dementia in your patient’s family. DNA banking allows your patient’s family to benefit from future scientific advances.

The online resource Gene Tests summarizes various commercial laboratories that offer DNA banking:

• Gene Tests, genetests.org/tests